tiprankstipranks
Fennec Pharmaceuticals (TSE:FRX)
TSX:FRX
Canadian Market
FRX
Fennec Pharmaceuticals
RESEARCH TOOLSreports

Fennec Pharmaceuticals (FRX) Stock Forecast & Price Target

36 Followers
See the Price Targets and Ratings of:

FRX Analyst Ratings

Strong Buy
5Ratings
Strong Buy
5 Buy
0 Hold
0 Sell
Based on 5 analysts giving stock ratings to
Fennec
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

FRX Stock 12 Month Forecast

Average Price Target

C$20.78
▲(156.52% Upside)
Based on 5 Wall Street analysts offering 12 month price targets for Fennec Pharmaceuticals in the last 3 months. The average price target is C$20.78 with a high forecast of C$24.93 and a low forecast of C$18.01. The average price target represents a 156.52% change from the last price of C$8.10.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"C$7","16":"C$16","25":"C$25","11.5":"C$11.5","20.5":"C$20.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":24.93406332,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">C$24.93</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20.7783861,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">C$20.78</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.00793462,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">C$18.01</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,11.5,16,20.5,25],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.89,10.124158716923077,11.358317433846153,12.592476150769231,13.826634867692308,15.060793584615384,16.294952301538462,17.52911101846154,18.763269735384615,19.99742845230769,21.231587169230767,22.465745886153847,23.699904603076924,{"y":24.93406332,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.89,9.804491238461539,10.718982476923077,11.633473715384616,12.547964953846154,13.462456192307691,14.376947430769231,15.291438669230768,16.20592990769231,17.120421146153845,18.03491238461538,18.949403623076922,19.863894861538462,{"y":20.7783861,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.89,9.591379586153847,10.292759172307694,10.994138758461538,11.695518344615385,12.396897930769232,13.098277516923076,13.799657103076923,14.50103668923077,15.202416275384616,15.903795861538462,16.605175447692307,17.306555033846152,{"y":18.00793462,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.21,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.55,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.25,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.29,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.01,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.33,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.99,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.59,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.17,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.6,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.205,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.79,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.89,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetC$24.93Average Price TargetC$20.78Lowest Price TargetC$18.01
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on TSE:FRX
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
C$18
Buy
122.18%
Upside
Reiterated
04/08/26
Buy Rating on PEDMARK Undervalues Global Expansion and Pipeline Upside, Supporting $13 Target Price
Craig-Hallum Analyst forecast on TSE:FRX
Chase Knickerbocker
Craig-Hallum
Craig-Hallum
―
Buy
―
Reiterated
04/07/26
Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (NASDAQ: DNLI) and Fennec Pharmaceuticals (NASDAQ: FENC)
Wedbush Analyst forecast on TSE:FRX
Unknown Analyst
Wedbush
Not Ranked
Wedbush
C$18
Buy
122.18%
Upside
Reiterated
03/25/26
Fennec Pharmaceuticals (FENC) Gets a Buy from Wedbush
Piper Sandler Analyst forecast on TSE:FRX
David Amsellem
Piper Sandler
Piper Sandler
C$24.92
Buy
207.63%
Upside
Reiterated
03/25/26
Piper Sandler Sticks to Their Buy Rating for Fennec Pharmaceuticals (FENC)
B. Riley Securities Analyst forecast on TSE:FRX
Madison Elsaadi
B. Riley Securities
B. Riley Securities
C$22.15
Buy
173.45%
Upside
Initiated
02/12/26
Fennec initiated with a Buy at B. RileyFennec initiated with a Buy at B. Riley
Maxim Group Analyst forecast on TSE:FRX
Jason McCarthy
Maxim Group
Maxim Group
C$20.77
Buy
156.36%
Upside
Reiterated
08/18/25
Fennec Pharmaceuticals' Promising Growth and Market Potential Drive Buy Rating
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on TSE:FRX
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
C$18
Buy
122.18%
Upside
Reiterated
04/08/26
Buy Rating on PEDMARK Undervalues Global Expansion and Pipeline Upside, Supporting $13 Target Price
Craig-Hallum Analyst forecast on TSE:FRX
Chase Knickerbocker
Craig-Hallum
Craig-Hallum
―
Buy
―
Reiterated
04/07/26
Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (NASDAQ: DNLI) and Fennec Pharmaceuticals (NASDAQ: FENC)
Wedbush Analyst forecast on TSE:FRX
Unknown Analyst
Wedbush
Not Ranked
Wedbush
C$18
Buy
122.18%
Upside
Reiterated
03/25/26
Fennec Pharmaceuticals (FENC) Gets a Buy from Wedbush
Piper Sandler Analyst forecast on TSE:FRX
David Amsellem
Piper Sandler
Piper Sandler
C$24.92
Buy
207.63%
Upside
Reiterated
03/25/26
Piper Sandler Sticks to Their Buy Rating for Fennec Pharmaceuticals (FENC)
B. Riley Securities Analyst forecast on TSE:FRX
Madison Elsaadi
B. Riley Securities
B. Riley Securities
C$22.15
Buy
173.45%
Upside
Initiated
02/12/26
Fennec initiated with a Buy at B. RileyFennec initiated with a Buy at B. Riley
Maxim Group Analyst forecast on TSE:FRX
Jason McCarthy
Maxim Group
Maxim Group
C$20.77
Buy
156.36%
Upside
Reiterated
08/18/25
Fennec Pharmaceuticals' Promising Growth and Market Potential Drive Buy Rating
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Fennec Pharmaceuticals

3 Months
xxx
Success Rate
11/23 ratings generated profit
48%
Average Return
+5.34%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 47.83% of your transactions generating a profit, with an average return of +5.34% per trade.
1 Year
Chase KnickerbockerCraig-Hallum
Success Rate
10/23 ratings generated profit
43%
Average Return
+1.55%
Copying Chase Knickerbocker's trades and holding each position for 1 Year would result in 43.48% of your transactions generating a profit, with an average return of +1.55% per trade.
2 Years
xxx
Success Rate
8/23 ratings generated profit
35%
Average Return
+2.34%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 34.78% of your transactions generating a profit, with an average return of +2.34% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

FRX Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
3
3
3
7
7
Buy
3
3
3
4
5
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
6
6
6
11
12
In the current month, FRX has received 12 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. FRX average Analyst price target in the past 3 months is 20.78.
Each month's total comprises the sum of three months' worth of ratings.

FRX Financial Forecast

FRX Earnings Forecast

Next quarter’s earnings estimate for FRX is -C$0.06 with a range of -C$0.18 to C$0.01. The previous quarter’s EPS was -C$0.23. FRX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year FRX has Performed in-line its overall industry.
Next quarter’s earnings estimate for FRX is -C$0.06 with a range of -C$0.18 to C$0.01. The previous quarter’s EPS was -C$0.23. FRX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year FRX has Performed in-line its overall industry.

FRX Sales Forecast

Next quarter’s sales forecast for FRX is C$20.39M with a range of C$18.87M to C$22.99M. The previous quarter’s sales results were C$19.21M. FRX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year FRX has Performed in-line its overall industry.
Next quarter’s sales forecast for FRX is C$20.39M with a range of C$18.87M to C$22.99M. The previous quarter’s sales results were C$19.21M. FRX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year FRX has Performed in-line its overall industry.

FRX Stock Forecast FAQ

What is TSE:FRX’s average 12-month price target, according to analysts?
Based on analyst ratings, Fennec Pharmaceuticals’s 12-month average price target is 20.78.
    What is TSE:FRX’s upside potential, based on the analysts’ average price target?
    Fennec Pharmaceuticals has 156.52% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is TSE:FRX a Buy, Sell or Hold?
          Fennec Pharmaceuticals has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Fennec Pharmaceuticals’s price target?
            The average price target for Fennec Pharmaceuticals is 20.78. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is C$24.93 ,the lowest forecast is C$18.01. The average price target represents 156.52% Increase from the current price of C$8.1.
              What do analysts say about Fennec Pharmaceuticals?
              Fennec Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
                How can I buy shares of TSE:FRX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.